Jennifer LaFemina to Aged
This is a "connection" page, showing publications Jennifer LaFemina has written about Aged.
Connection Strength
0.222
-
Lim PW, Dinh KH, Sullivan M, Wassef WY, Zivny J, Whalen GF, LaFemina J. Thirty-day outcomes underestimate endocrine and exocrine insufficiency after pancreatic resection. HPB (Oxford). 2016 Apr; 18(4):360-6.
Score: 0.039
-
LaFemina J, Chou JF, G?nen M, Rocha FG, Correa-Gallego C, Kingham TP, Fong Y, D'Angelica MI, Jarnagin WR, DeMatteo RP, Allen PJ. Hepatic arterial nodal metastases in pancreatic cancer: is this the node of importance? J Gastrointest Surg. 2013 Jun; 17(6):1092-7.
Score: 0.032
-
Lafemina J, Katabi N, Klimstra D, Correa-Gallego C, Gaujoux S, Kingham TP, Dematteo RP, Fong Y, D'Angelica MI, Jarnagin WR, Do RK, Brennan MF, Allen PJ. Malignant progression in IPMN: a cohort analysis of patients initially selected for resection or observation. Ann Surg Oncol. 2013 Feb; 20(2):440-7.
Score: 0.031
-
LaFemina J, Qin LX, Moraco NH, Antonescu CR, Fields RC, Crago AM, Brennan MF, Singer S. Oncologic outcomes of sporadic, neurofibromatosis-associated, and radiation-induced malignant peripheral nerve sheath tumors. Ann Surg Oncol. 2013 Jan; 20(1):66-72.
Score: 0.031
-
LaFemina J, Vagefi PA, Warshaw AL, Fern?ndez-del Castillo C. Transgastric pancreaticogastric anastomosis: an alternative operative approach for middle pancreatectomy. Arch Surg. 2010 May; 145(5):476-81.
Score: 0.026
-
Laskiewicz L, Jamshed S, Gong Y, Ainechi S, LaFemina J, Wang X. The diagnostic value of FNA biopsy in grading pancreatic neuroendocrine tumors. Cancer Cytopathol. 2018 03; 126(3):170-178.
Score: 0.011
-
Dinh KH, Harris AF, LaFemina J, Whalen GF, Sullivan M, Licho R, Hill T, Lambert LA. Advantages of day-before lymphoscintigraphy and undiluted methylene blue dye injections for sentinel lymph node biopsies for melanoma. J Surg Oncol. 2016 Dec; 114(8):947-950.
Score: 0.010
-
Tan MC, Basturk O, Brannon AR, Bhanot U, Scott SN, Bouvier N, LaFemina J, Jarnagin WR, Berger MF, Klimstra D, Allen PJ. GNAS and KRAS Mutations Define Separate Progression Pathways in Intraductal Papillary Mucinous Neoplasm-Associated Carcinoma. J Am Coll Surg. 2015 May; 220(5):845-854.e1.
Score: 0.009
-
Do RK, Katz SS, Gollub MJ, Li J, LaFemina J, Zabor EC, Moskowitz CS, Klimstra DS, Allen PJ. Interobserver agreement for detection of malignant features of intraductal papillary mucinous neoplasms of the pancreas on MDCT. AJR Am J Roentgenol. 2014 Nov; 203(5):973-9.
Score: 0.009
-
Correa-Gallego C, Do R, Lafemina J, Gonen M, D'Angelica MI, DeMatteo RP, Fong Y, Kingham TP, Brennan MF, Jarnagin WR, Allen PJ. Predicting dysplasia and invasive carcinoma in intraductal papillary mucinous neoplasms of the pancreas: development of a preoperative nomogram. Ann Surg Oncol. 2013 Dec; 20(13):4348-55.
Score: 0.008
-
Frankel TL, LaFemina J, Bamboat ZM, D'Angelica MI, DeMatteo RP, Fong Y, Kingham TP, Jarnagin WR, Allen PJ. Dysplasia at the surgical margin is associated with recurrence after resection of non-invasive intraductal papillary mucinous neoplasms. HPB (Oxford). 2013 Oct; 15(10):814-21.
Score: 0.008
-
O'Neill CB, Atoria CL, O'Reilly EM, LaFemina J, Henman MC, Elkin EB. Costs and trends in pancreatic cancer treatment. Cancer. 2012 Oct 15; 118(20):5132-9.
Score: 0.007